-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fluocinolone Acetonide SR in Retinopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fluocinolone Acetonide SR in Retinopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fluocinolone Acetonide SR in Retinopathy Drug Details: Fluocinolone acetonide (Iluvien,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Nodal Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Nodal Marginal Zone B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Nodal Marginal Zone B-Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Diabetic Macular Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Diabetic Macular Edema Drug Details: Vorolanib is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Wet (Neovascular / Exudative) Macular...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Non-Proliferative Diabetic Retinopathy (NPDR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Non-Proliferative Diabetic Retinopathy (NPDR) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Non-Proliferative Diabetic Retinopathy (NPDR) Drug Details: Vorolanib...
-
Product Insights
NewNet Present Value Model: Spruce Biosciences Inc’s Tildacerfont
Empower your strategies with our Net Present Value Model: Spruce Biosciences Inc's Tildacerfont report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: EyePoint Pharmaceuticals Inc’s Vorolanib
Empower your strategies with our Net Present Value Model: EyePoint Pharmaceuticals Inc's Vorolanib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a pharmaceutical company that develops and commercializes therapies for treatment of eye disorders. The company utilizes its Duraset platform, a miniaturized, injectable, and sustained delivery system to develop its product. Its pipeline products includes EYP-1901, an investigational sustained delivery intravital anti-VEGF treatment that targets wet age-related macular degeneration (Wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macularedema (DME). The company also markets its product such as Yutiq, a fluocinolone acetonide intravitreal implant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fluocinolone Acetonide SR in Posterior Uveitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fluocinolone Acetonide SR in Posterior Uveitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fluocinolone Acetonide SR in Posterior Uveitis Drug Details: Fluocinolone acetonide...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Non-Proliferative Diabetic Retinopathy (NPDR)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Non-Proliferative Diabetic Retinopathy (NPDR) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Non-Proliferative Diabetic Retinopathy (NPDR) Drug Details: Vorolanib is...